45P - The association of the level serum of interleukin-10 and its polymorphism gene with the risk and the prognosis for colorectal cancer in tunisia. (45P)

Date 08 December 2017
Event ESMO Immuno-Oncology Congress 2017
Session Lunch & Poster Display session
Topics Gynaecologic Malignancies
Presenter Jihene Braham
Citation Annals of Oncology (2017) 28 (suppl_11): xi6-xi29. 10.1093/annonc/mdx711
Authors J.A. Braham, M. Balti, B.A. Mouna, B. Sinda, H. Meriem, A. Zribi, B.N. Sonia, F. Sana, A. Haddaoui
  • Medical Oncology, MILITARY HOSÏTAL, 1008 - TUNIS/TN



Interleukin 10 (IL-10) is considered an immune modulator cytokine, showing both antitumor and pro-tumor characteristics. Its role in the pathogenesis and progression of colorectal cancer depends on microenvironmental milieu.


A case–control study with 195 newly diagnosed colorectal cancer (CRC) patients, and 195 healthy individuals was conducted to compare the serum IL-10 levels between patients and controls and investigate the involvement of the polymorphism (-1082) A/G of the promoter region of the anti-inflammatory cytokine IL10 in the development of CRC. Serum levels of IL10 were measured by Enzyme amplified sensitivity immunoassay (EASIA) method; genotype and allele frequencies of IL10 (-1082) A/G were assessed using amplified Refractory Mutation System (ARMS_PCR).


Mean serum IL-10 levels were significantly higher in CRC patients than in controls (27.56 +/- 13.59 versus 2.39 +/- 1.4 pg/ml; P = 0.001). CRC patients with worse prognosis at the time of diagnosis tend to have higher levels of circulating IL-10 than those with better prognosis (34.77 +/- 12.37 pg/ml). This study has demonstrated also that the minor allele G was a protective factor against the occurrence of CRC (OR = 0.52; p 


Our results demonstrated that IL-10 levels in the serum of CRC patients can be used as a prognostic biomarker in CRC patients and show a negative association of the minor allele G and GG genotype with CRC, and the AG genotype has a more protective role against the occurrence of CRC than does the AA genotype.

Clinical trial identification

Legal entity responsible for the study

Military Hospital


Military Hospital


All authors have declared no conflicts of interest.